FIMM and Science for Life Laboratory, Karolinska Institutet
Päivi Östling obtained her PhD thesis at the Turku Centre for Biotechnology in 2006, and did her postdoctoral training at the Medical Biotechnology, Technical Research Centre of Finland (VTT) in 2006-2011. During her post-doctoral training, she worked on cell-based gain-of-function screening of microRNAs combined with reverse-phase protein arrays (RPPA). To date she has participated in several RNAi and cell-based functional screening projects in prostate and breast cancer. As a senior researcher at the Institute for Molecular Medicine Finland, FIMM, she has set-up comprehensive drug sensitivity profiling for patient-derived cells from prostate and renal cancer (Saeed et al., Eur Urol 2016). This work has been part of a large team science effort lined to the “Grand Challenge” on Individualized Systems Medicine that was initiated in leukemia (reviewed in Pemovska Drug Discovery 2015, Horvath et al., Nature Review Drug Discovery 2016). Since September 2016, Päivi Östling has a joint affiliation at FIMM and Science for Life Laboratory, the Department of Oncology and Pathology at the Karolinska Institutet, where her task is to set-up and develop drug sensitivity profiling as a co-Principal Investigator at the Olli Kallioniemi research group.